209 related articles for article (PubMed ID: 17912014)
1. In vivo radioiodide imaging and treatment of pancreatic cancer xenografts after MUC1 promoter-driven expression of the human sodium-iodide symporter.
Chen RF; Li ZH; Pan QH; Zhou JJ; Tang QB; Yu FY; Zhou QB; Wang J; Chen JS
Pancreatology; 2007; 7(5-6):505-13. PubMed ID: 17912014
[TBL] [Abstract][Full Text] [Related]
2. In vivo radioiodide imaging and treatment of breast cancer xenografts after MUC1-driven expression of the sodium iodide symporter.
Dwyer RM; Bergert ER; O'connor MK; Gendler SJ; Morris JC
Clin Cancer Res; 2005 Feb; 11(4):1483-9. PubMed ID: 15746050
[TBL] [Abstract][Full Text] [Related]
3. Adenovirus-mediated and targeted expression of the sodium-iodide symporter permits in vivo radioiodide imaging and therapy of pancreatic tumors.
Dwyer RM; Bergert ER; O'Connor MK; Gendler SJ; Morris JC
Hum Gene Ther; 2006 Jun; 17(6):661-8. PubMed ID: 16776574
[TBL] [Abstract][Full Text] [Related]
4. Sodium iodide symporter-mediated radioiodide imaging and therapy of ovarian tumor xenografts in mice.
Dwyer RM; Bergert ER; O'Connor MK; Gendler SJ; Morris JC
Gene Ther; 2006 Jan; 13(1):60-6. PubMed ID: 16121204
[TBL] [Abstract][Full Text] [Related]
5. Probasin promoter (ARR(2)PB)-driven, prostate-specific expression of the human sodium iodide symporter (h-NIS) for targeted radioiodine therapy of prostate cancer.
Kakinuma H; Bergert ER; Spitzweg C; Cheville JC; Lieber MM; Morris JC
Cancer Res; 2003 Nov; 63(22):7840-4. PubMed ID: 14633711
[TBL] [Abstract][Full Text] [Related]
6. [Human mucin 1 promoter drives human sodium/iodide symporter gene targeting expression in pancreatic carcinoma cells].
Zhou QB; Chen RF; Li ZH; Pan QH; Zhou JJ; Tang QB; Chen JS
Zhonghua Yi Xue Za Zhi; 2007 Oct; 87(39):2780-4. PubMed ID: 18167272
[TBL] [Abstract][Full Text] [Related]
7. Functional sodium iodide symporter expression in breast cancer xenografts in vivo after systemic treatment with retinoic acid and dexamethasone.
Willhauck MJ; Sharif-Samani B; Senekowitsch-Schmidtke R; Wunderlich N; Göke B; Morris JC; Spitzweg C
Breast Cancer Res Treat; 2008 May; 109(2):263-72. PubMed ID: 17636401
[TBL] [Abstract][Full Text] [Related]
8. Radioiodide treatment after sodium iodide symporter gene transfer is a highly effective therapy in neuroendocrine tumor cells.
Schipper ML; Weber A; Béhé M; Göke R; Joba W; Schmidt H; Bert T; Simon B; Arnold R; Heufelder AE; Behr TM
Cancer Res; 2003 Mar; 63(6):1333-8. PubMed ID: 12649195
[TBL] [Abstract][Full Text] [Related]
9. Treatment of prostate cancer by radioiodine therapy after tissue-specific expression of the sodium iodide symporter.
Spitzweg C; O'Connor MK; Bergert ER; Tindall DJ; Young CY; Morris JC
Cancer Res; 2000 Nov; 60(22):6526-30. PubMed ID: 11103823
[TBL] [Abstract][Full Text] [Related]
10. Rat sodium iodide symporter for radioiodide therapy of cancer.
Mitrofanova E; Unfer R; Vahanian N; Daniels W; Roberson E; Seregina T; Seth P; Link C
Clin Cancer Res; 2004 Oct; 10(20):6969-76. PubMed ID: 15501976
[TBL] [Abstract][Full Text] [Related]
11. Telomerase-driven expression of the sodium iodide symporter (NIS) for in vivo radioiodide treatment of cancer: a new broad-spectrum NIS-mediated antitumor approach.
Riesco-Eizaguirre G; De la Vieja A; Rodríguez I; Miranda S; Martín-Duque P; Vassaux G; Santisteban P
J Clin Endocrinol Metab; 2011 Sep; 96(9):E1435-43. PubMed ID: 21697253
[TBL] [Abstract][Full Text] [Related]
12. AFP promoter enhancer increased specific expression of the human sodium iodide symporter (hNIS) for targeted radioiodine therapy of hepatocellular carcinoma.
Ma XJ; Huang R; Kuang AR
Cancer Invest; 2009 Jul; 27(6):673-81. PubMed ID: 19241193
[TBL] [Abstract][Full Text] [Related]
13. Construction of an MUC-1 promoter driven, conditionally replicating adenovirus that expresses the sodium iodide symporter for gene therapy of breast cancer.
Trujillo MA; Oneal MJ; Davydova J; Bergert E; Yamamoto M; Morris JC
Breast Cancer Res; 2009; 11(4):R53. PubMed ID: 19635153
[TBL] [Abstract][Full Text] [Related]
14. Transcriptional tumor-selective promoter targeting of E. coli purine nucleoside phosphorylase for pancreatic cancer suicide gene therapy.
Deharvengt S; Wack S; Aprahamian M; Hajri A
J Gene Med; 2005 May; 7(5):672-80. PubMed ID: 15580629
[TBL] [Abstract][Full Text] [Related]
15. Enhancement of sodium/iodide symporter expression in thyroid and breast cancer.
Kogai T; Taki K; Brent GA
Endocr Relat Cancer; 2006 Sep; 13(3):797-826. PubMed ID: 16954431
[TBL] [Abstract][Full Text] [Related]
16. Use of rhenium-188 for in vivo imaging and treatment of human cervical cancer cells transfected with lentivirus expressing sodium iodide symporter.
Zhang M; Shi S; Guo R; Miao Y; Li B
Oncol Rep; 2016 Oct; 36(4):2289-97. PubMed ID: 27573304
[TBL] [Abstract][Full Text] [Related]
17. Alpha-fetoprotein promoter-targeted sodium iodide symporter gene therapy of hepatocellular carcinoma.
Willhauck MJ; Sharif Samani BR; Klutz K; Cengic N; Wolf I; Mohr L; Geissler M; Senekowitsch-Schmidtke R; Göke B; Morris JC; Spitzweg C
Gene Ther; 2008 Feb; 15(3):214-23. PubMed ID: 17989705
[TBL] [Abstract][Full Text] [Related]
18. Image-guided radioiodide therapy of medullary thyroid cancer after carcinoembryonic antigen promoter-targeted sodium iodide symporter gene expression.
Spitzweg C; Baker CH; Bergert ER; O'Connor MK; Morris JC
Hum Gene Ther; 2007 Oct; 18(10):916-24. PubMed ID: 17931047
[TBL] [Abstract][Full Text] [Related]
19. Doxorubicin enhances the expression of transgene under control of the CMV promoter in anaplastic thyroid carcinoma cells.
Kim KI; Kang JH; Chung JK; Lee YJ; Jeong JM; Lee DS; Lee MC
J Nucl Med; 2007 Sep; 48(9):1553-61. PubMed ID: 17704247
[TBL] [Abstract][Full Text] [Related]
20. Dual therapy of ovarian cancer using measles viruses expressing carcinoembryonic antigen and sodium iodide symporter.
Hasegawa K; Pham L; O'Connor MK; Federspiel MJ; Russell SJ; Peng KW
Clin Cancer Res; 2006 Mar; 12(6):1868-75. PubMed ID: 16551872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]